Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$3.5 million.

  • Tg Therapeutics' Non Operating Income rose 5767.82% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.3 million, marking a year-over-year increase of 3817.64%. This contributed to the annual value of -$16.3 million for FY2024, which is 11575.75% down from last year.
  • Per Tg Therapeutics' latest filing, its Non Operating Income stood at -$3.5 million for Q3 2025, which was up 5767.82% from -$3.9 million recorded in Q2 2025.
  • Tg Therapeutics' Non Operating Income's 5-year high stood at $3.6 million during Q1 2025, with a 5-year trough of -$8.2 million in Q3 2024.
  • For the 5-year period, Tg Therapeutics' Non Operating Income averaged around -$1.7 million, with its median value being -$1.5 million (2023).
  • As far as peak fluctuations go, Tg Therapeutics' Non Operating Income skyrocketed by 43438.6% in 2023, and later plummeted by 38562.43% in 2024.
  • Tg Therapeutics' Non Operating Income (Quarter) stood at -$391000.0 in 2021, then crashed by 138.36% to -$932000.0 in 2022, then plummeted by 65.34% to -$1.5 million in 2023, then tumbled by 191.76% to -$4.5 million in 2024, then grew by 23.13% to -$3.5 million in 2025.
  • Its Non Operating Income was -$3.5 million in Q3 2025, compared to -$3.9 million in Q2 2025 and $3.6 million in Q1 2025.